** Shares of Boston-based drug developer PepGen PEPG.O fall 9% to $2.56 premarket
** Company says it will temporarily pause mid-stage study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD)
** Says the study is paused until company can review results from patient group dosed with 10 mg/kg, which is expected during Q3
** DMD is a genetic disorder causing progressive muscle weakness and degeneration
** Company says no new safety issues related to PGN-EDO51 have been observed since the company's last safety update in January
** PEPG has fallen 83% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。